-
Phase 1
-
-
18+Age Range
-
10Locations
-
Recruiting
Menu
Looking for a Clinical Trial?
Our trials are organized by Research Area — broad categories of health conditions being studied at BMS.
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Recruiting
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Study Arms
Experimental: Part 1: Dose Escalation BMS-986497 (Monotherapy)
Study Arms
Experimental: Part 2, Cohort A: Dose Expansion BMS-986497 (Combination Therapy)
Study Arms
Experimental: Part 2, Cohort B: Dose Expansion BMS-986497 (Triple Combination Therapy)